Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.

doi:10.1158/2159-8290.CD-20-0672

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.

Cancer discovery - 1 Feb 2021

Montesion Meagan, Murugesan Karthikeyan, Jin Dexter X, Sharaf Radwa, Sanchez Nora, Guria Ameet, Minker Max, Li Gerald, Fisher Virginia, Sokol Ethan S, Pavlick Dean C, Moore Jay A, Braly Alan, Singal Gaurav, Fabrizio David, Comment Leah A, Rizvi Naiyer A, Alexander Brian M, Frampton Garrett M, Hegde Priti S, Albacker Lee A

Abstract excerpt

Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH in oncogenesis and treatment, we utilized a pan-cancer genomic dataset of 83,644 patient samples, a small subset of which had treatment outcomes with immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Carcinoma, Non-Small-Cell Lung

Share to HLA Antigens

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Escape

Source

Open in PubMed

Identifiers

PMID: 33127846
DOI: 10.1158/2159-8290.CD-20-0672

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.PMID 33127846Read ↗

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.Semantic proximity Read ↗

Genetic immune escape landscape in primary and metastatic cancerSemantic proximity Read ↗

Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.Semantic proximity Read ↗

Genetic immune escape landscape in primary and metastatic cancer.Semantic proximity Read ↗

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.Semantic proximity Read ↗

Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance.Semantic proximity Read ↗

HLA allele-specific expression loss in tumors can shorten survival and hinder immunotherapySemantic proximity Read ↗

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapySemantic proximity Read ↗

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.